Evidence map›Paper›PMID 39298113›Full record

Observational studyJournal of endocrinological investigation2025

Serum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma.

Antonella Verrienti, Valeria Pecce, Giorgio Grani, Valeria Del Gatto, Samuele Barp, Marianna Maranghi, Laura Giacomelli, Cira Di Gioia, Marco Biffoni, Sebastiano Filetti and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Antonella Verrienti *Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy. antonella.verrienti@uniroma1.it.ORCID http://orcid.org/0000-0002-3603-5972
Valeria Pecce *Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy.
Giorgio GraniDepartment of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy.
Valeria Del GattoDepartment of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy.
Samuele BarpDepartment of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy.
Marianna MaranghiDepartment of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy.
Laura GiacomelliDepartment of Surgical Sciences, Sapienza University of Rome, Rome, 00161, Italy.
Cira Di GioiaDepartment of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Rome, 00161, Italy.
Marco BiffoniDepartment of Surgical Sciences, Sapienza University of Rome, Rome, 00161, Italy.
Sebastiano FilettiDepartment of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy.
Cosimo DuranteDepartment of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy.
Marialuisa SponzielloDepartment of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePapillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm, accounting for approximately 85% of all follicular cell-derived thyroid nodules. This study aimed to assess the diagnostic potential of circulating microRNA-146a-5p and microRNA-221-3p as biomarkers for PTC and their usefulness in monitoring disease progression during patient follow-up.

methodsAn observational study was conducted on two cohorts of PTC patients and healthy controls (HCs) using digital PCR. We collected patients' clinical, biochemical, and imaging data during the post-surgery surveillance. We analyzed the levels of circulating miRNAs in serum samples of patients before surgery and during the follow-up, including those with indeterminate/biochemical incomplete response (IndR/BIR) and residual thyroid tissues (Thy Residue).

resultsBoth miR-146a-5p and miR-221-3p were confirmed as effective biomarkers for PTC diagnosis. They enabled differentiation between pre-surgery PTC patients and HCs with an area under the curve (AUC) of 92% and 87.3%, respectively, using a threshold level of 768,545 copies/uL for miR-146a-5p and 389,331 copies/uL for miR-221-3p. It was found that miRNA fold change levels, rather than absolute levels, can be useful during patient follow-up. In particular, we found that a fold change of 2 for miR-146a-5p and 2.2 for miR-221-3p can identify a progressive disease, regardless of the presence of TgAbs or remnant thyroid.

conclusionMiRNA-146a-5p and miRNA-221-3p, particularly the former, could be valuable diagnostic biomarkers for PTCs. They also seem to be effective in monitoring disease progression during patient follow-up by evaluating their fold change, even when thyroglobulin is uninformative.

Indexed as

Biomarkers, TumorMicroRNAsThyroid Cancer, PapillaryThyroid NeoplasmsAdultCase-Control StudiesDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisBiomarkers, TumorMicroRNAsMIR221, humanMIRN146 microRNA, humanBiomarkersCirculating miRNALiquid biopsyPapillary thyroid cancerPatient follow-up

Identifiers

PMID39298113
PMCPMC11876262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.